Please select the eligibility criteria that correspond to the clinical trial below.
Title: A Comparison of Drug Eluting and Bare Metal Stents With or Without Abciximab in ST Segment Elevation Myocardial Infarction The Eindhoven Reperfusion Study
Brief Summary: The DEBATER study is designed to determine the superiority of abciximab over no abciximab and to determine the superiority of drug eluting stents over bare metal stents in patients with acute myocardial infarction who undergo percutaneous coronary intervention.


Options:
A: Inclusion Criteria:

* Must have clinical symptoms consistent with AMI (e.g., angina or anginal equivalent)lasting \>20 minutes but \<12 hours in duration;
* ST-segment elevation of \>1 mm in \>2 contiguous leads, or (presumably new) left bundle branch block, or true posterior MI with ST depression of \>1 mm in \>2 contiguous anterior leads;
* The patient or guardian agrees to the study protocol and the schedule of clinical and angiographic follow-up, and provides informed, written consent.

Exclusion Criteria:

* The patient has a known hypersensitivity or contraindication to any of the following medications:

  * Heparin, pork or pork products
  * Both abciximab and eptifibatide
  * Aspirin
  * Both Clopidogrel and Ticlopidine
  * Bivalirudin
  * Paclitaxel or Taxol
  * The polymer components of the TAXUS™ stent (SIBS)
  * Stainless steel and/or
  * Contrast media;
* Prior administration of thrombolytic therapy, bivalirudin, GP IIb/IIIa inhibitors, low molecular weight heparin or fondaparinux for this admission. Patients receiving prior unfractionated heparin may be enrolled, and treated per randomization;
* Current use of coumadin;
* Systemic (intravenous) Paclitaxel or Taxol use within 12 months;
* Female of childbearing potential, unless a recent pregnancy test is negative, who possibly plans to become pregnant any time after enrollment into this study;
* History of bleeding diathesis or known coagulopathy (including heparin-induced thrombocytopenia), or will refuse blood transfusions;
* History of intra-cerebral mass, aneurysm, arteriovenous malformation, or hemorrhagic stroke;
* Stroke or transient ischemic attack within the past 6 months, or any permanent residual neurologic defect;
* Gastrointestinal or genitourinary bleeding within the last 2 months, or major surgery within six weeks;
* Recent history or known current platelet count \<100,000 cells/mm3 or Hgb \<10 g/dL;
* Extensive peripheral vascular disease, such that emergent angiography and intervention in the opinion of the investigator is likely to be difficult or complicated;
* An elective surgical procedure is planned that would necessitate interruption of thienopyridines during the first six months post enrollment;
* Non-cardiac co-morbid conditions are present with life expectancy \<1 year or that may result in protocol non-compliance;
* Patients who are actively participating in another drug or device investigational study, which have not completed the primary endpoint follow-up period;
* Previous enrollment in this trial;
* Patients who underwent coronary stent implantation within the past 30 days.
B: Inclusion Criteria:

1. Have prolonged, continuous (lasting at least 20 minutes) chest pain despite administration of nitrates and onset within 12 hours of randomization, and one of the following:

   1. ST segment elevation \>=1mm in standard leads and \>=2mm in 2 or more contiguous precordial leads with reciprocal ST depression
   2. New or presumably new left bundle branch block (LBBB)
2. The culprit lesion must be identified on a de novo native coronary artery and an emergency angioplasty must be possible. The culprit site must be visualized before the stent implantation;

Exclusion Criteria:

1. Killip class \> 2 upon arrival to the cath-lab;
2. Significant (\>50%) stenosis proximal or distal to the target lesion that might require revascularization or impede inflow or runoff;
3. Evidence of massive thrombus in the infarct related artery distally to the culprit lesion;
4. Documented left ventricular ejection fraction \<=30%;
5. Target lesion is located in an arterial or venous by-pass graft;
6. ECG documented evidence of prior myocardial infarction;
7. Patient who received thrombolytic therapy for the current AMI before enrollment in this study.
C: Inclusion Criteria:

* STEMI ≤ 12 hours (or STEMI equivalent).
* No contra - indications for primary PCI.
* No contra - indications for abciximab.
* Informed consent from the patient.

Exclusion Criteria:

* Contra - indication for primary PCI: History of peripheral/coronary artery disease that is inaccessible for angiography or PCI.
* Contra - indications for GPI: Ongoing bleeding, bleeding diathesis, cerebrovascular accident \< 6 months, major surgery/trauma \< 6 months, platelet count \< 100.000 mm3 , intracranial arteriovenous malformation or neoplasm, malignant hypertension, INR \>1.5, severe hepatic dysfunction
* Contra - indications for clopidogrel:

  * Severe liver dysfunction, pathological bleeding disorders such as peptic ulcer or intracranial bleeding.
  * Thrombolytic therapy \< 24 hours.
  * Therapy with GPI \< 24 hours.
  * Anticoagulation therapy.
* Co - morbid conditions with a predictable fatal outcome in the short run.
* No informed consent: refusal, coma, artificial respiration, impaired mentation.
D: Inclusion Criteria

* 18 years of age
* ST-segment elevation (more than 2mm in more than contiguous leads)
* MI with symptom onset less than 12h
* The patient is willing to comply with specified follow-up evaluations
* Signed ICF
* Single de novo lesion in the target (culprit) vessel
* Target lesion maximum length is 33 mm (by visual estimation)
* Reference vessel diameter must be more than 3.0 to less than 4.0 mm by visual estimation
* Randomization should occur as soon as Presence of TIMI 2 or 3 before randomization Exclusion Criteria
* Pregnant or nursing patients
* Left Bundle Branch Block (LBBB), paced rhythm, or other Electrocardiogram (ECG) abnormality
* Impaired renal function
* Prior coronary artery bypass graft surgery
* Bleeding diathesis
* Contraindication to aspirin
* cardiopulmonary resuscitation
* Cardiogenic shock
* chronic warfarin anticoagulation
* LVEF less than 20%
* other medical illness
* participation in another investigational drug or device study that has not reached its primary endpoint
* Left main coronary artery disease with 50% stenosis
* Ostial target lesion
* Failure to visualize vessel anatomy distal to the culprit lesion
* Moderate to heavily calcified target lesion or vessel
* excessive tortuosity
* bifurcation with a side branch more than 2.0 mm in diameter
* A significant (greater than 50%) stenosis proximal or distal to the target lesion is present that cannot be covered by same single stent
* Diffuse disease distal to target lesion with impaired runoff
* Any prior stent proximal to the target lesion, or within 10 mm distal of the target lesion
* PCI of another lesion performed within 6 months before the index procedure
* Target lesion located in a saphenous vein graft

Answer: C